On September 9, 2020 Cleave Therapeutics, Inc., a clinical-stage biopharmaceutical company focused on VCP/p97 as a novel target in oncology, reported that it has entered into a preclinical research collaboration with Jazz Pharmaceuticals, a global biopharmaceutical company developing life-changing medicines for people with serious diseases (Press release, Cleave Therapeutics, SEP 9, 2020, View Source [SID1234564853]).
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
Under the terms of the agreement, Cleave will conduct preclinical research studies evaluating CB-5339, its second-generation, small molecule VCP/p97 inhibitor, in combination with Vyxeos (daunorubicin and cytarabine) liposome for injection, approved in the U.S. and Europe for newly diagnosed therapy-related acute myeloid leukemia (t-AML) or AML with myelodysplasia-related changes (AML-MRC).
CB-5339 plays a key role in DNA damage repair and has demonstrated impressive preclinical activity and synergy in combination with DNA-damaging agents. Vyxeos, a unique liposomal formulation of daunorubicin and cytarabine at a fixed 1:5 molar ratio, has been shown to have synergistic effects at killing leukemia cells in vitro and in murine models.
"With 75,000 newly diagnosed AML patients worldwide each year, there is an urgent need to advance new treatment options," said Amy Burroughs, president and chief executive officer of Cleave Therapeutics. "As we evaluate CB-5339 as a single agent in human Phase 1 studies, we are excited to collaborate with Jazz Pharmaceuticals on preclinical studies to explore the potential of CB-5339 in combination with Vyxeos."
About Vyxeos (daunorubicin and cytarabine)
In the U.S., Vyxeos (daunorubicin and cytarabine) is a liposomal formulation of a fixed combination of daunorubicin and cytarabine for intravenous infusion that represents the first, only and most proven chemotherapy treatment option specifically for two types of high-risk, secondary acute myeloid leukemia (AML): newly diagnosed therapy-related AML (t-AML) and AML with myelodysplasia-related changes (AML-MRC). In Europe, Vyxeos Liposomal (daunorubicin/cytarabine) is indicated for the treatment of adults with newly diagnosed, therapy-related acute myeloid leukemia (t-AML) or AML with myelodysplasia-related changes (AML-MRC). Vyxeos is currently approved in more than 30 countries. Through a robust clinical development program, Vyxeos is being evaluated across multiple AML populations.